Tobin Marcus, Wolfe Research policy and politics head, joins CNBC's 'Squawk Box' to discuss what Trump's pick for HHS ...
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Eli Lilly and (NYSE:LLY) with a Outperform ...
Wolfe Research initiated coverage of Veracyte (VCYT) with an Outperform rating and $50 price target Published first on TheFly – the ...
Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...
Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...
Wolfe Research has recently raised Warner Bros Discovery Inc (WBD) stock to Peer Perform rating, as announced on November 11, 2024, according to Finviz. Earlier, on August 13, 2024, Bernstein had ...
Wolfe Research has upgraded Warner Bros. Discovery (WBD, Financials) to "peer perform" from "underperform," citing a balanced risk/reward outlook despite Warner Bros. Discoverys $40 billion in ...
Investing.com - Wolfe Research has upgraded shares of Warner Bros. Discovery (NASDAQ: NASDAQ: WBD) to Peer Perform from ...
Investing.com - Wolfe Research has upgraded shares of Warner Bros. Discovery (NASDAQ:WBD) to Peer Perform from Underperform following its Q3 results last week, and assigned a fair value range of $ ...
Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer Perform, citing higher confidence in the company's dominance in the ...
Fintel reports that on November 12, 2024, Wolfe Research downgraded their outlook for Alnylam Pharmaceuticals (LSE:0HD2) from Peer Perform to Underperform. There are 1,155 funds or institutions ...
Wolfe Research downgraded Alnylam (ALNY) to Underperform from Peer Perform with a $205 price target The firm cites expectations that the company will expand its approved Amvuttra into the much ...